LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 107 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,935,485 | $52,403,228 | 3.69% |
Raffles Associates | 1,536,946 | $2,305,419 | 3.14% |
Defender Capital, LLC. | 5,136,085 | $7,704,128 | 2.69% |
Prescott General Partners LLC | 1,851,851 | $2,777,777 | 0.22% |
DAFNA Capital Management LLC | 140,000 | $210,000 | 0.06% |
Beirne Wealth Consulting Services, LLC | 45,000 | $67,500 | 0.05% |
CTC Capital Management, LLC | 14,100 | $21,150 | 0.04% |
Diametric Capital, LP | 50,875 | $76,313 | 0.04% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $1,172,649 | 0.03% |
One68 Global Capital, LLC | 13,377 | $20,066 | 0.03% |